Michel Tulliez

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

Gabriel Étienne, Joëlle Guilhot, Delphine Réa et al. · Journal of Clinical Oncology · 2016 · 494 citations

Medicine, Hematology, Pharmacotherapy +15

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

Philippe Rousselot, Aude Charbonnier, Pascale Cony‐Makhoul et al. · Journal of Clinical Oncology · 2013 · 409 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Delphine Réa, Franck E. Nicolini, Michel Tulliez et al. · Blood · 2016 · 317 citations · Full text

Medicine, Hematology, Oncology +8

Etiology of portal vein thrombosis in adults

Dominique Valla, Nicole Casadevall, Marie‐Geneviève Huisse et al. · Gastroenterology · 1988 · 240 citations

Medicine, Internal Medicine, Gastroenterology +11

Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients

Laurence Valeyrie, Sylvie Bastuji‐Garin, J. Revuz et al. · Journal of the American Academy of Dermatology · 2003 · 231 citations

Medicine, Hematology, Oncology +13